biostudies-literaturevan den Berg SAMedtronicHealth~HollandTop Sector Life Sciences & HealthTop Sector Life Sciences &amp; HealthHartstichtingHersenstichting383https://www.ebi.ac.uk/biostudies/studies/S-EPMC6595565biostudies-literatureUnknown20(1)<h4>Background</h4>Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin) in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.<h4>Methods</h4>MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded oTrialsMulticentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial.PMC6595565HA2015.01.06LSHM17016CVON2015-01: CONTRASTNederkoorn PJvan den Berg SAFransen PSSvan der Worp HBMR ASAP InvestigatorsSiegers AHofmeijer JCaminada KKerkhoff Hde Leeuw FEKruyt NDDippel DWJfalseMulticentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial.<h4>Background</h4>Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin) in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.<h4>Methods</h4>MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded o2019-01-01T00:00:00Z2019 Jun2026-05-05T01:15:52.992Z2019-08-12T07:02:13ZS-EPMC65955653124293110.1186/s13063-019-3419-z